Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-RAGE Inhalation Solution in Asthma and Inflammatory Lung Disease
2023-509654-60-00Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jul 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised trial of ARO-RAGE in asthma and inflammatory lung disease (2 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Started Jul 2024; status: completed.
02
Drugs
ARO-RAGE
03
Conditions
asthmainflammatory lung disease
Beyond the preview
Go deeper on 2023-509654-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509654-60-00.